Spain (ES)

COVID-19 SEVERITY AND VACCINE BREAKTHROUGH INFECTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES, OTHER SYSTEMIC AUTOIMMUNE AND INFLAMMATORY DISEASES, AND HEALTHY INDIVIDUALS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY. (2022) Gupta L, Hoff LS, R N, Sen P, Katsuyuki Shinjo S, Day J, Lilleker JB, et al. Conference contribution IMPAIRED PROMIS PHYSICAL FUNCTION IN IDIOPATHIC INFLAMMATORY MYOPATHY PATIENTS: RESULTS FROM THE MULTICENTER COVAD PATIENT REPORTED E-SURVEY (2022) Yoshida A, Kim M, Kuwana M, R N, Lilleker JB, Sen P, Agarwal V, et al. Conference contribution TREATMENT PATTERNS OF IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM AN INTERNATIONAL COHORT OF OVER 1,400 PATIENTS (2022) Aoude M, Gupta L, Hmamouchi I, Grignaschi S, Cavagna L, Kim M, R N, et al. Conference contribution HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY. (2022) Grignaschi S, Cavagna L, Kim M, R N, Lilleker JB, Sen P, Agarwal V, et al. Conference contribution PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT (2022) Elhai M, Boubaya M, Sritharan N, Balbir-Gurman A, Siegert E, Hachulla E, De Vries-Bouwstra J, et al. Conference contribution CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE. (2022) Lescoat A, Huang S, Carreira P, Siegert E, De Vries-Bouwstra J, Distler J, Smith V, et al. Conference contribution GLUCOCORTICOIDS PRESCRIBING PRACTICES IN SYSTEMIC SCLEROSIS: AN ANALYSIS OF THE EUSTAR DATABASE. (2022) Iudici M, Mongin D, Siegert E, Carreira P, Distler J, Henes J, Zanatta E, et al. Conference contribution PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE (2022) Sarbu AC, Guler S, Stadler O, Allanore Y, Bernardino V, Distler J, Gabrielli A, et al. Conference contribution ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL (2022) D'Agostino MA, Boers M, Schett G, Conaghan PG, Naredo E, Mandl P, Carron P, et al. Conference contribution